Mortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia

BMC Infectious Diseases

Girmay Medhin³  Sibhatu Biadgilign²  Gobena Ameni¹  Belete Getahun³ 

[1] Armauer Hansen Research Institute, PO Box 1005, Addis Ababa, Ethiopia;Department of Epidemiology and Biostatistics, Jimma University, College of Public Health and Medical Science, Ethiopia P.O.Box 24414, Addis Ababa, Ethiopia;Aklilu Lemma Institute of Pathobiology, College of Health Sciences Addis Ababa University, PO Box 1176, Addis Ababa, Ethiopia

关键词: Ethiopia;    DOTS;    tuberculosis;    cohort;    Mortality;   

Others  :  1175722
DOI  :  10.1186/1471-2334-11-127

 received in 2010-10-21, accepted in 2011-05-16,  发布年份 2011

【 摘 要 】

Background

Tuberculosis (TB) is the leading cause of mortality among infectious diseases worldwide. Ninty five percent of TB cases and 98% of deaths due to TB occur in developing countries. Globally, the mortality rate has declined with the introduction of effective anti TB chemotherapy. Nevertheless, some patients with active TB still die while on treatment for their disease. In Ethiopia, little is known on survival and risk factors for mortality among a cohort of TB patients. The objective of the study is to determine the magnitude and identify risk factors associated with time to death among TB patients treated under DOTS programme in Addis Ababa, Ethiopia.

Methods

This is a retrospective cohort study. Data was obtained by assessing medical records of TB patients registered from June 2004 to July 2009 G.C and treated under the DOTS strategy in three randomly selected health centers. A step-wise multivariable Cox's regression model and Kaplan- Meier curves were used to model the outcome of interest. Mortality was used as an outcome measure. Person-years of observation (PYO) were calculated from the date of starting anti-TB treatment to date of outcome and was calculated as the number of deaths/100 PYO. Statistical analysis SPSS version 16 was used for data analysis and results were reported significant whenever P-value was less than 5%.

Results

From a total of 6,450 registered TB patients 236(3.7%) were died. More than 75% death occurred within eight month of treatment initiation. The mean and median times of survival starting from the date of treatment initiation were 7.2 and 7.9 months, respectively. Comparison of survival curves using Kaplan Meier curves method with log-rank test showed that the survival status was significantly different between patient categories as well as across treatment centers (P < 0.05). The death rate of pulmonary positive, pulmonary negative and extra pulmonary TB patients were 2.7%, 3.6%, and 4.3%, respectively. Body weight at initiation of anti-TB treatment (<35 kg), patient category, year of enrollment and treatment center were independent predictors for time to death.

Conclusions

Most of the patients were died at the end of treatment period. This underlines the need for devising a mechanism of standardizing the existing DOTS programme and nutritional support for underweight patients for better clinical and treatment outcome.

【 授权许可】

   
2011 Getahun et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]World Health Organization: Global Tuberculosis Control: a short update to the 2009 report. [http://www.who.int/tb/publications/global_report/2009/update/en/index.html] webciteWorld Health Organization; 2009. Accessed at March 20, 2011
• [2]World Health Organization: Global Tuberculosis Control Surveillance, Planning, Financing. [http://www.who.int/tb/publications/global_report/2005/en/] webciteWorld Health Organization; 2005. Accessed at March 20, 2011
• [3]Federal Ministry of Health of Ethiopia (FMOH): Guidelines for program and clinical management of drug resistant tuberculosis. In Addis Ababa. First edition. FMOH; 2009.
• [4]World Health Organization: Country Profile: Ethiopia, Global Tuberculosis Control Surveillance, Planning, Financing, Who Report. 2008, 105-108. WHO/HTM/TB/2008.393
• [5]Ministry of Health of Ethiopia (MOH): Tuberculosis, Leprosy and TB/HIV Prevention and Control Programme Manual. 4th edition. Addis Ababa: MOH; 2008.
• [6]Toungoussova OS, Nizovtseva NI, Mariandyshev AO, Caugant DA, Sandven P, Bjune G: Impact of drug-resistant Mycobacterium tuberculosis on treatment outcome of culture-positive cases of tuberculosis in the Archangel oblast, Russia, in 1999. Eur J Clin Microbiol Infect Dis 2004, 23:174-179.
• [7]Shilova MV: Specific features of the spread of tuberculosis in Russia at the end of the 20th century. Ann N Y Acad Sci 2001, 953:124-132.
• [8]Atun RA, Samyshkin YA, Drobniewski F, et al.: Barriers to sustainable tuberculosis control in the Russian Federation health system. Bull World Health Organ 2005, 83:217-223.
• [9]Vasankari T, Holmstrom P, Ollgren J, Liippo K, Kokki M, Ruutu P: Risk factors for poor tuberculosis treatment outcome in Finland: a cohort study. BMC Public Health 2007, 7:291. BioMed Central Full Text
• [10]Zevallos M, Justman JE: Tuberculosis in the elderly. ClinGeriatr Med 2003, 19:121-138.
• [11]Summary and Statistical Report of the 2007 Population and Housing Census Results. 51 [http://www.csa.gov.et/pdf/Cen2007_prelimineray.pdf] webcite
• [12]Federal Ministry of Health (FMOH), Planning and Programming Department: Health and Health Related Indicators. EC. Addis Ababa, Ethiopia; 2000.
• [13]WHO Tuberculosis Programme: Framework for effective tuberculosis control. In WHO document. WHO/TB/94. Geneva, Switzerland: World Health Organization; 1994:179.
• [14]Bao QS, Du YH, Lu CY: Treatment outcome of new pulmonary tuberculosis in Guangzhou, China 1993-2002: a register-based cohort study. BMC Public Health 2007, 7:344. BioMed Central Full Text
• [15]Xianyi C, Fengzeng Z, Hongjin D, Liya W, Lixia W, Xin D, Chin DP: The DOTS strategy in China: results and lessons after 10 years. Bull World Health Organ 2002, 80(6):430-6.
• [16]Zellweger JP, Coulon P: Outcome of patients treated for tuberculosis in Vaud County, Switzerland. Int J Tuberc Lung Dis 1998, 2(5):372-7.
• [17]Vasantha M, Gopi PG, Subramani R: Survival of tuberculosis patients treated under DOTS in a rural Tuberculosis Unit (TU), south India. Indian J Tuberc 2008, 55(2):64-9.
• [18]Kolappan C, Subramani R, Karunakaran K, Narayanan PR: Mortality of tuberculosis patients in Chennai, India. Bull World Health Organ 2006, 84:555-560.
• [19]Santha T, Garg R, Frieden TR, Chandrasekaran V, Subramani R, Gopi PG, Selvakumar N, Ganapathy S, Charles N, Rajamma J, Narayanan PR: Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000. Int J Tuberc Lung Dis 2002, 6(9):780-8.
• [20]Borgdorff MW, Veen J, Kalisvaart NA, Nagelkerke N: Mortality among tuberculosis patients in The Netherlands in the period 1993-1995. Eur Respir J 1998, 11(4):816-20.
• [21]Lawn SD, Acheampong JW: Pulmonary tuberculosis in adults: factors associated with mortality at a Ghanaian teaching hospital. West Afr J Med 1999, 18:270-274.
• [22]Tan KL, Sin Fam Lam KN, Chew LS: Mortality of patients while on treatment for active tuberculosis. Singapore Med J 1996, 37:258-260.
• [23]Harries AD, Hargreaves NJ, Gausi F, Kwanjana JH, Salaniponi FM: High early death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis 2001, 5:1000-1005.
• [24]Vree M, Huong NT, Duong BD, Sy DN, Van le N, Co NV, Cobelens FG, Borgdorff MW: Mortality and failure among tuberculosis patients who did not complete treatment in Vietnam: a cohort study. BMC Public Health 2007, 7:134. BioMed Central Full Text
• [25]Humphries MJ, Byfield SP, Darbyshire JH, et al.: Deaths occurring in newly notified patients with pulmonary tuberculosis in England and Wales. Br J Dis Chest 1984, 78:149-158.
• [26]Walpola HC, Siskind V, Patel AM, Konstantinos A, Derhy P: Tuberculosis-related deaths in Queensland, Australia, 1989-1998: characteristics and risk factors. Int J Tuberc Lung Dis 2003, 7:742-750.
• [27]Fielder JF, Chaulk CP, Dalvi M, Gachuhi R, Comstock GW, Sterling TR: A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis 2002, 6:1114-1117.
• [28]Kolappan C, Subramani R, Kumaraswami V, Santha T, Narayanan PR: Excess mortality and risk factors for mortality among a cohort of TB patients from rural South India. Int J Tuberc Lung Dis 2008, 12:81-86.
• [29]Datiko DG, Lindtjorn B: Mortality in successfully treated tuberculosis patients in southern Ethiopia: retrospective follow-up study. Int J Tuberc Lung Dis 2010, 14(7):1-6.
• [30]Khan A, Timothy R, Reves R, Andrew V, Robert HC, the Tuberculosis Trails Consortium: Lack of weight gains and relapse risk in a large Tuberculosis treatment trial. Am. J Respir. Crit. Care Med 2006, 174:344-48.
• [31]Kim HJ, Kwon SY, Yoon HI, Lee CT, Kim YW, Chung HS, Han SK, Shim YS, Lee JH: Nutritional deficit as a negative prognostic factor in patients with miliary tuberculosis. Eur Respir J 2008, 32(4):1031-6.
• [32]Kim HJ, Lee CH, Shin S, Lee JH, Kim YW, Chung HS, Han SK, Shim YS, Kim DK: The impact of nutritional deficit on mortality of in-patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 2010, 14(1):79-85.
• [33]Wen CP, Chan TC, Chan HT, Tsai MK, Cheng TY, Tsai SP: The reduction of tuberculosis risks by smoking cessation. BMC Infect Dis 2010, 10:156. BioMed Central Full Text
• [34]Shen X, Deriemer K, Yuan Z, Shen M, Xia Z, Gui X, Wang L, Mei J: Deaths among tuberculosis cases in Shanghai, China: who is at risk? BMC Infect Dis 2009, 9:95. BioMed Central Full Text
• [35]Nunn P, Brindle R, Carpenter L, Odhiambo J, Wasunna K, Newnham R, Githui W, Gathua S, Omwega M, McAdam K: Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. Am Rev Respir Dis 1992, 146(4):849-54.
• [36]Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR: Nonadherence in tuberculosis treatment: predictors and consequences in New York city. Am J Med 1997, 102:164-170.
• [37]Goble N, Iseman MD, Madson LA, Waite D, Ackerson L, Horsburgh CR Jr: Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. N Eng J Med 1993, 328:527-532.
• [38]Frieden TR, Sterling T, Pablos-Mendez A, et al.: The emergence of drug resistant tuberculosis in New York City. N Engl J Med 1993, 328:521-526.
• [39]Datta M, Radhamani MP, Selvaraj R, et al.: Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme. Tubercle Lung Dis 1993, 74:180-186.
• [40]Kang'ombe C, et al.: High mortality rates in tuberculosis patients in Zomba Hospital, Malawi, during 32 months of follow-up. Trans R Soc Trop Med Hyg 2000, 94:305-309.
• [41]Buhl K, Nyboe J: Epidemiological basis of tuberculosis eradication - 9. Changes in the mortality of Danish tuberculosis patients since 1925. Bull WHO 1967, 37:907-925.
• [42]White MC, Portillo CJ: Tuberculosis mortality associated with AIDS and drug or alcohol abuse: analysis of multiple cause-of-death data. Publ Health 1996, 110:185-189.
• [43]Heldal E, Naalsund A, Kongerud J, Tverdal A, Boe J: Deaths from active tuberculosis: can we rely on notification and mortality figures? Tubercle Lung Dis 1996, 77:215-219.